Kiniksa Pharmaceuticals, Ltd. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report; quarterly financial results are not clearly provided in the filing text. The registrant is identified in the filing as Kiniksa Pharmaceuticals, Ltd.
Business context and reporting period
Kiniksa is an early-commercial-stage biopharmaceutical company developing therapies for inflammatory and immunological diseases. Its portfolio includes ARCALYST (rilonacept), mavrilimumab, vixarelimab and KPL-404. ARCALYST was approved in March 2021 for recurrent pericarditis, and the company began U.S. sales in April. It also assumed U.S. sales and distribution for ARCALYST’s previously approved indications. Profits on ARCALYST sales are shared equally with Regeneron after specified costs.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Product revenue, net | $38.5 million | None |
| Cost of goods sold | $9.1 million | None |
| Research and development expense | $99.3 million | $112.0 million |
| Selling, general and administrative expense | $85.9 million | $45.3 million |
| Operating loss | $156.6 million | $157.4 million |
| Net loss | $157.9 million | $161.4 million |
| Net loss per share, basic and diluted | $2.30 | $2.61 |
| Cash used in operating activities | $126.3 million | $136.5 million |
| Cash, cash equivalents and short-term investments at year-end | $182.2 million | $323.5 million |
Revenue began in 2021 following ARCALYST’s approval. The filing states the ARCALYST franchise became profitable in the fourth quarter after three quarters of commercial availability; this does not mean Kiniksa as a whole was profitable. The filing does not provide a clear standalone quarterly revenue, profit or margin value. No borrowings are identified in the provided financial statements; year-end liabilities included $6.1 million of operating lease liabilities. Cash flow from investing activities was a $128.6 million inflow, largely reflecting maturities of short-term investments, and financing activities provided $5.9 million, principally from employee share plans. Cash and cash equivalents increased $8.2 million during the year.
Material changes versus the prior comparable period
- Net product revenue rose from zero to $38.5 million as U.S. ARCALYST sales commenced.
- SG&A increased $40.6 million, or 90%, largely due to building the commercial organization and ARCALYST launch marketing.
- R&D decreased $12.7 million, or 11%, mainly following completion of the pivotal recurrent-pericarditis trial and lower related program costs; spending increased for mavrilimumab, vixarelimab and KPL-404.
- Net loss narrowed by $3.5 million, while year-end cash, cash equivalents and short-term investments fell by $141.3 million from 2020.
- The company paid a $20.0 million ARCALYST regulatory milestone to Regeneron, capitalized as an intangible asset and amortized over 20 years.
Outlook, management commentary and key risks
- Management expected year-end cash, cash equivalents and short-term investments to fund operations and capital expenditures for at least 12 months from issuance of the financial statements. Continued viability thereafter depends on ARCALYST sales and/or additional financing. Management expects operating losses to continue.
- Kiniksa expected top-line results from the vixarelimab Phase 2b prurigo nodularis trial in the second half of 2022. It initiated a Phase 2 proof-of-concept KPL-404 trial in rheumatoid arthritis in December 2021.
- Mavrilimumab’s Phase 3 COVID-19-related ARDS trial missed its primary endpoint in December 2021; the company decided not to pursue that indication, while completing the trial. In February 2022, after year-end, Kiniksa said it would not initiate a Phase 3 GCA trial.
- In February 2022, after year-end, Kiniksa granted Huadong exclusive Asia-Pacific rights, excluding Japan, to ARCALYST and mavrilimumab. The agreements provide a $22 million upfront payment and eligibility for up to approximately $640 million in contingent development, regulatory and sales milestones.
- Manufacturing is a material risk: Regeneron and its contractors are the sole ARCALYST suppliers. Manufacturing events in 2021 delayed distribution of some material, although the company reported sourcing enough supply for current commercial needs. The filing also describes reliance on third parties for other clinical and commercial manufacturing.
- Other significant risks include uncertain market adoption and reimbursement, clinical and regulatory uncertainty, COVID-19 disruption, competition, intellectual-property protection and future capital needs. The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor’s opinion on the financial statements was unqualified.
Important facts for investors to verify
- Obtain quarterly disclosures to verify ARCALYST sales trends and the reported fourth-quarter franchise profitability; annual figures do not show the quarter-level detail.
- Track ARCALYST access, payer coverage, patient demand, net pricing and the impact of the 50/50 profit-sharing arrangement with Regeneron.
- Assess manufacturing supply, including the resolution of the 2021 distribution delays and the company’s ability to secure adequate future supply.
- Review cash burn, remaining liquidity runway and financing needs against the company’s stated 12-month funding expectation and ongoing losses.
- Verify the timing and results of the vixarelimab Phase 2b trial and KPL-404 Phase 2 trial, and evaluate portfolio priorities following the mavrilimumab setbacks.
- Review the Huadong agreements’ terms, milestone conditions and any subsequent payments; the potential contingent amount is not guaranteed revenue.
- Consider disclosed commitments, including $45.4 million of minimum payments under manufacturing agreements, of which $32.4 million was due within one year, as well as license obligations and potential royalties.